CSIMarket



Evolutionary Genomics Inc.  (FNAM)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

FNAM's Income from Cont. Operations Growth by Quarter and Year

Evolutionary Genomics's Income from Cont. Operations results by quarter and year




FNAM Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -2.26 0.54 -0.16
III Quarter September - -0.55 -0.29 -0.18
II Quarter June -0.53 -0.51 -0.24 -0.20
I Quarter March -0.52 -1.71 -0.25 -0.19
FY   -1.05 -5.03 -0.24 -0.73



FNAM Income from Cont. Operations second quarter 2022 Y/Y Growth Comment
Evolutionary Genomics Inc. in the second quarter 2022 recorded loss from continued operations of $ -0.53 millions.

According to the results reported in the second quarter 2022, Evolutionary Genomics Inc. achieved the best Income from Cont. Operations growth in Medical Laboratories industry. While Evolutionary Genomics Inc.' s Income from Cont. Operations no change of % ranks overall at the positon no. in the second quarter 2022.




FNAM Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Evolutionary Genomics's second quarter 2022 Income from Cont. Operations $ -0.53 millions FNAM's Income Statement
Evolutionary Genomics's second quarter 2021 Income from Cont. Operations $ -0.51 millions Quarterly FNAM's Income Statement
New: More FNAM's historic Income from Cont. Operations Growth >>


FNAM Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Evolutionary Genomics's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FNAM's II. Quarter Q/Q Income from Cont. Operations Comment
Current results of -0.53 millions by Evolutionary Genomics Inc. look even worse compare to the loss from continued operations -0.52 millions in the first quarter.

Within Medical Laboratories industry Evolutionary Genomics Inc. achieved highest sequential Income from Cont. Operations growth. While Evolutionary Genomics's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FNAM's II. Quarter Q/Q Income from Cont. Operations Comment
II. Quarter 2022 results of -0.53 millions by Evolutionary Genomics Inc. appear even less good if you take a look at -0.52 millions a quarter before.

Within Medical Laboratories industry Evolutionary Genomics Inc. achieved highest sequential Income from Cont. Operations growth. While Evolutionary Genomics's Income from Cont. Operations growth quarter on quarter, overall rank is .


Evolutionary Genomics's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ -3.87 $ -3.85 $ -5.04 $ -2.24 $ -1.98
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Evolutionary Genomics Inc.' has realized cumulative trailing twelve months loss from continued operations of $ -4 millions in the Jun 30 2022 period.
The situation is worsening as the cumulative loss from continued operations is getting bigger from $ -3.85 millions in the twelve months ending a quarter before and $ -0.52 millions for the twelve months ending in the quarter Mar 31 2021 Pranav Jayaraman  told.

Evolutionary Genomics Inc. achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Evolutionary Genomics Inc.' has realized cumulative trailing twelve months loss from continued operations of $ -4 millions in the Jun 30 2022 period.
The situation is getting worse as the cumulative loss from continued operations is becoming larger from $ -3.85 millions in the twelve months ending a quarter before and $ -0.52 millions from the TTM period ending Mar 31 2021.

Evolutionary Genomics Inc. achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Medical Laboratories Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
FNAM's Income from Cont. Operations Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for FNAM's Competitors
Income from Cont. Operations Growth for Evolutionary Genomics's Suppliers
Income from Cont. Operations Growth for FNAM's Customers

You may also want to know
FNAM's Annual Growth Rates FNAM's Profitability Ratios FNAM's Asset Turnover Ratio FNAM's Dividend Growth
FNAM's Roe FNAM's Valuation Ratios FNAM's Financial Strength Ratios FNAM's Dividend Payout Ratio
FNAM's Roa FNAM's Inventory Turnover Ratio FNAM's Growth Rates FNAM's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Jun 30 2022
Atrion Corporation4.75%$ 4.751 millions
Pacira Biosciences inc.4.17%$ 4.166 millions
Zoetis Inc.3.52%$ 3.523 millions
Corcept Therapeutics Inc3.30%$ 3.299 millions
Biogen Inc.3.24%$ 3.237 millions
Orthofix Medical Inc.2.85%$ 2.851 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

IRAA's Profile

Stock Price

IRAA's Financials

Business Description

Fundamentals

Charts & Quotes

IRAA's News

Suppliers

IRAA's Competitors

Customers & Markets

Economic Indicators

IRAA's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071